Clinical trials
Prostatic Neoplasms trials in Mexico
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
55 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 3 |
| 2004 | 1 |
| 2005 | 1 |
| 2006 | 1 |
| 2007 | 3 |
| 2008 | 3 |
| 2009 | 5 |
| 2010 | 3 |
| 2011 | 2 |
| 2012 | 1 |
| 2013 | 4 |
| 2014 | 1 |
| 2015 | 2 |
| 2016 | 1 |
| 2017 | 3 |
| 2018 | 1 |
| 2020 | 6 |
| 2021 | 1 |
| 2022 | 2 |
| 2023 | 1 |
| 2025 | 6 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 30 |
| Active, not recruiting | 13 |
| Recruiting | 7 |
| Terminated | 2 |
| No longer available | 1 |
| Approved for marketing | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| AstraZeneca | 6 |
| Bristol-Myers Squibb | 5 |
| Aragon Pharmaceuticals, Inc. | 4 |
| Ferring Pharmaceuticals | 4 |
| Sanofi | 4 |
| Amgen | 2 |
| Celgene | 2 |
| Instituto Mexicano del Seguro Social | 2 |
| Janssen Research & Development, LLC | 2 |
| Merck Sharp & Dohme LLC | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Prostatic Neoplasms | 55 |
| Neoplasms | 5 |
| Breast Neoplasms | 3 |
| Neoplasm Metastasis | 3 |
| Urogenital Neoplasms | 3 |
| Bone Diseases, Metabolic | 2 |
| Carcinoma | 2 |
| Colorectal Neoplasms | 2 |
| Genital Diseases, Male | 2 |
| Genital Neoplasms, Male | 2 |
Trials
Showing 26 to 50 of 55. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.